Scientists ask: Without trial data, how can we trust Russia's Covid vaccine? | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
July 04, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JULY 04, 2025
Scientists ask: Without trial data, how can we trust Russia's Covid vaccine?

Coronavirus chronicle

Reuters
11 August, 2020, 07:20 pm
Last modified: 11 August, 2020, 11:40 pm

Related News

  • Syria receives first shipment of Russian shots - report
  • Young Pakistanis rush to purchase Russian vaccine as private sales open
  • Africa proves rocky terrain for Russian and Chinese vaccines
  • EU says no talks under way to buy Russia's Covid-19 vaccine
  • EU regulator says Russia yet to submit Covid-19 vaccine application

Scientists ask: Without trial data, how can we trust Russia's Covid vaccine?

Russian President Vladimir Putin said the vaccine, developed by Moscow's Gamaleya Institute, was safe and that it had been administered to one of his daughters

Reuters
11 August, 2020, 07:20 pm
Last modified: 11 August, 2020, 11:40 pm
FILE PHOTO: A scientist prepares samples during the research and development of a vaccine against the coronavirus disease (Covid-19) at a laboratory of BIOCAD biotechnology company in Saint Petersburg, Russia June 11, 2020. REUTERS/Anton Vaganov/File Photo
FILE PHOTO: A scientist prepares samples during the research and development of a vaccine against the coronavirus disease (Covid-19) at a laboratory of BIOCAD biotechnology company in Saint Petersburg, Russia June 11, 2020. REUTERS/Anton Vaganov/File Photo

An announcement by Russia on Tuesday that it will approve a Covid-19 vaccine after less than two months of human testing prompted alarm among global health experts, who said that with no full trial data, the vaccine is hard to trust.

Intent on being first in the global race to develop a vaccine against the pandemic disease, Russia has yet to conduct large-scale trials of the shot that would produce data to show whether it works - something immunologists and infectious disease experts say could be a "reckless" step.

"Russia is essentially conducting a large population level experiment," said Ayfer Ali, a specialist in drug research at Britain's Warwick Business School.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

She said such a super-fast approval could mean that potential adverse effects of a vaccine may not be picked up. These, while likely to be rare, could be serious, she warned.

Russian President Vladimir Putin said the vaccine, developed by Moscow's Gamaleya Institute, was safe and that it had been administered to one of his daughters.

"I know that it works quite effectively, forms strong immunity, and I repeat, it has passed all the needed checks," Putin said on state television.

Francois Balloux, an expert at University College London's Genetics Institute, said it was "a reckless and foolish decision".

"Mass vaccination with an improperly tested vaccine is unethical," he said. "Any problem with the Russian vaccination campaign would be disastrous both through its negative effects on health, but also because it would further set back the acceptance of vaccines in the population."

SCIENTIFIC PAPERS

His comments were echoed by Danny Altmann, a professor of Immunology at Imperial College London, who said the "collateral damage" from deploying any vaccine that is not yet known to be safe and effective "would exacerbate our current problems insurmountably".

Even as Russia declared victory, more than half a dozen drugmakers around the world are in the process of conducting large-scale, advanced human trials of their potential Covid-19 vaccines, each with tens of thousands of volunteer participants.

Several of these frontrunners, including Moderna, Pfizer and AstraZeneca, say they hope to know if their vaccines work and are safe by the end of this year.

All are expected to publish their trial results and safety data and submit them to regulators in the United States, Europe and elsewhere for scrutiny before any licence could be granted.

The Russian vaccine's approval by the Health Ministry comes before trials that would normally involve thousands of participants, commonly known as a Phase III trial. Such trials are usually considered essential precursors for a vaccine to secure regulatory approval.

Peter Kremsner, an expert at Germany's University Hospital in Tuebingen who is working on clinical trials of a vaccine candidate from CureVac, said Russia's move was "reckless".

"Normally you need a large number of people to be tested before you approve a vaccine," he said. "I think it's reckless to do that if lots of people haven't already been tested."

Experts said the lack of published data on Russia's vaccine - including how it is made and details on safety, immune response and whether can prevent Covid-19 infection - leaves scientists, health authorities and the public in the dark.

"It is not possible to know if the Russian vaccine has been shown to be effective without submission of scientific papers for analysis," said Keith Neal, a specialist in the epidemiology of infectious diseases at Britain's Nottingham University.

Top News

Russian Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • RAB speaks to media on 4 July 2025. Photo: Collected
    Dispute between brothers behind rape of woman in Cumilla's Muradnagar: RAB
  • NCP Convener Nahid Islam speaks at a public gathering in Thakurgaon on 4 July 2025. Photo: UNB
    NCP fighting for an equal, democratic Bangladesh: Nahid
  • A head-on collision between a bus and a truck on the Dhaka-Pabna Highway in Santhia upazila of Pabna district on 4 July 2025.Photo: UNB
    Bus-truck collision leaves 3 dead, 10 injured in Pabna

MOST VIEWED

  • History in women's football: Bangladesh qualify for Asian Cup for the first time
    History in women's football: Bangladesh qualify for Asian Cup for the first time
  • What it will take to merge crisis-hit Islamic banks
    What it will take to merge crisis-hit Islamic banks
  • Govt to pay 3-year high ACU bill of $2b next week
    Govt to pay 3-year high ACU bill of $2b next week
  • 3 July 2024: Momentum builds as quota protest enters third day
    3 July 2024: Momentum builds as quota protest enters third day
  • Photo: Collected
    Court orders seizure of S Alam Group assets over Tk10,280cr defaulted loan
  • Sabir Mustafa. Sketch: TBS
    Has the time come for Bangladesh to embrace PR? 

Related News

  • Syria receives first shipment of Russian shots - report
  • Young Pakistanis rush to purchase Russian vaccine as private sales open
  • Africa proves rocky terrain for Russian and Chinese vaccines
  • EU says no talks under way to buy Russia's Covid-19 vaccine
  • EU regulator says Russia yet to submit Covid-19 vaccine application

Features

The July Uprising saw people from all walks of life find themselves redrawing their relationship with politics. Photo: Mehedi Hasan

Red July: The political awakening of our urban middle class

7h | Panorama
Illustration: TBS

Grameen Jibon: A business born from soil, memory, and the scent of home

10h | Features
Illustration: TBS

Why rare earth elements matter more than you think

20h | The Big Picture
Illustration: TBS

The buildup to July Uprising: From a simple anti-quota movement to a wildfire against autocracy

1d | Panorama

More Videos from TBS

Contractor witnesses shooting of hungry people in Gaza

Contractor witnesses shooting of hungry people in Gaza

1h | TBS Stories
Russia first country to recognize Taliban rule

Russia first country to recognize Taliban rule

4h | TBS World
Patiya Police Station OC Withdrawn Amid Protests: What Experts Are Saying

Patiya Police Station OC Withdrawn Amid Protests: What Experts Are Saying

18h | Podcast
Food aid in Gaza is a death trap!

Food aid in Gaza is a death trap!

19h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net